InvestorsHub Logo
Followers 16
Posts 1063
Boards Moderated 0
Alias Born 09/01/2019

Re: CanadianBeaver post# 13031

Wednesday, 12/16/2020 5:10:57 PM

Wednesday, December 16, 2020 5:10:57 PM

Post# of 16706
A MUCH better PR, thanks CM.
Of course this is relevant and the new PR better explains it. There is a huge current need for successful Treatments. COVID isnt going away soon, XMas travel, vaccinations starting in spring with distribution and logistics issues. 40% wont take it and 20% still wont wear masks...

Blue Crystal balls say AGN will have data early, by January and apply for FDA EUA using time off ventilators and less time in hospital for patients...


The firm noted that this suggests that patients may be recovering more quickly with Ifenprodil, which might help in reducing the number of days required for hospitalization. The company pointed out that even though the average number of days in the hospital is not one of the exact predetermined metrics included in the interim analysis, this data will be included in the final data set as some other firms have been successful at gaining emergency use authorization from the U.S. Food and Drug Administration based solely upon the ability to reduce the number of in-hospital days.


The company's CEO Christopher J. Moreau remarked, "While we are very pleased that the interim data has provided us with some positive trending information, we still need to evaluate the full definitive results and statistics to be presented with the final data set...We will be especially interested to see the numbers on the overall time spent on ventilation and rate to ventilation to be reported in the final data set."


Thanks to K*

https://www.streetwisereports.com/article/2020/12/16/pharma-developer-reports-interim-data-is-trending-positively-in-phase-2b-3-covid-19-trial.html